Developer docs
API playgroundTry for free, no card

Search company profiles

XaTek

Full company profile

uuid00031tv

Namestring
XaTek
Legal namestring
XaTek Inc.
Websiteurl
clotchip.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

XaTek Inc. is a privately held, Cleveland, Ohio-based biomedical company founded in 2016 that develops ClotChip, a portable point-of-care medical device for assessing whole-blood coagulation. The device applies miniaturized dielectric spectroscopy — originally developed over eight years by an electrical engineering team at Case Western Reserve University — to single-drop whole-blood samples obtained via routine finger stick. ClotChip quantitatively measures blood impedance without requiring application-specific reagents and is agnostic to the underlying cause of a coagulation defect, enabling use across multiple clinical markets including congenital hemophilia, direct oral anticoagulant (DOAC) therapy monitoring, trauma-induced coagulopathy, and pre-surgical screening. The company received FDA Breakthrough Device Designation in March 2020 and remains in the clinical trials phase, with completed and ongoing studies across University Hospitals Cleveland (including Rainbow Babies & Children Hospital), the Cleveland VA, and Cleveland Clinic's Global Cardiovascular Innovations Center, as well as a DoD/U.S. Navy-funded ruggedization program for field trauma use.

XaTek operates a B2B enterprise sales motion targeting clinical care facilities, research centers, pharmaceutical companies, and device/diagnostic companies. The company is headquartered administratively in Hudson, Ohio, while maintaining laboratory operations at the Cleveland Clinic Global Cardiovascular Innovations Center. Leadership consists of President & CEO John Zak and a team described as experienced medical device market disrupters and inventors. The underlying revenue model is expected to be hardware sales of the ClotChip device to clinical institutions, with potential recurring revenue from consumables or service agreements, though the company is pre-commercial and no pricing, ARR, or revenue figures have been publicly disclosed. XaTek has raised at least $9.1 million in a disclosed funding round (July 2018) and operates with 1–10 employees, consistent with a clinical-stage medical device company preparing for regulatory clearance and commercial launch.

Short descriptiontext

XaTek Inc. is a Cleveland, Ohio-based biomedical company developing ClotChip, a portable point-of-care device that uses miniaturized dielectric spectroscopy to assess whole-blood coagulation from a finger-stick sample. It targets hemophilia, DOAC monitoring, trauma, and pre-surgical clinical markets, and is currently in clinical trials following its 2020 FDA Breakthrough Device Designation.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCleveland, United States
HQ citystring
Cleveland
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
point-of-care diagnostics, blood coagulation testing, hemostasis monitoring, portable medical devices, dielectric spectroscopy
Industry3 codes
PRIMARYHLAHACAD
Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLAHAFAI
Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Point-of-Care Blood Coagulation Diagnostics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

ClotChip is a portable point-of-care medical device. Revenue model likely involves device sales to clinical facilities and healthcare providers, with potential recurring revenue from consumables or service agreements.

clotchip.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1ClotChip
Description

A portable, point-of-care device capable of providing both quantitative and qualitative measurements relevant to a patient's entire hemostatic process using miniaturized dielectric spectroscopy.

clotchip.com
Core offering1 text field

XaTek Inc. develops and is commercializing ClotChip, a portable point-of-care medical device that uses proprietary miniaturized dielectric spectroscopy to evaluate whole-blood coagulation from a single finger-stick blood drop. The device delivers both quantitative and qualitative measurements of the hemostatic process without requiring application-specific reagents, and is intended for use in clinical care, trauma field assessment, anticoagulant therapy monitoring, hemophilia management, and pre-surgical screening. The company is pre-commercial with the device currently in clinical studies after receiving FDA Breakthrough Device Designation in March 2020.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Currently in clinical trials - N=100 pre-surgical screening study completed
+3 more records
Product overview1 text field

XaTek offers a single unified product: ClotChip, a portable point-of-care device for blood coagulation assessment. ClotChip leverages proprietary miniaturized dielectric spectroscopy technology to analyze whole-blood samples and provide rapid clinical evaluation of coagulation at the point of care, serving markets including congenital blood disorders, anticoagulant therapy monitoring, trauma care, and pre-surgical screening.

Product and service1 record
1ClotChip
CategoryPoint-of-care coagulation diagnostic device
Description

ClotChip is a portable, point-of-care medical device that uses proprietary miniaturized dielectric spectroscopy to analyze single-drop whole-blood samples obtained from a routine finger stick. The device provides both quantitative and qualitative measurements relevant to a patient's entire hemostatic process, detecting both non-cellular (coagulation factors) and cellular (platelet) abnormalities without requiring application-specific reagents. It serves clinical care facilities, hemophilia treatment centers, anticoagulant therapy monitoring, trauma care, and pre-surgical screening use cases.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1U.S. Food and Drug Administration (FDA)
Strategic tierCoreTypeOthersAnnounced on2020-03-01
Description

FDA granted Breakthrough Device Designation to ClotChip in March 2020, providing expedited review pathway and regulatory recognition of the device's potential to provide more effective treatment or diagnosis of life-threatening diseases.

clotchip.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Department of Defense's Combat Readiness Medical Research Program, in cooperation with the U.S. Navy, funded the ruggedization of ClotChip for field use in trauma settings including ambulances and helicopters.

Strategic tierCoreTypeTechnology or Integration
Description

Technology origin - Case Western Reserve University electrical engineering team developed dielectric spectroscopy technology over more than eight years. XaTek licensed/commercialized this technology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborative research partnership for device development and testing. XaTek maintains laboratory facilities at this location.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Multiple clinical trials including hypercoagulability in COVID-19 infections study and hemophilia sensitivity studies (N=100). Active research partnership for clinical validation.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical study on ClotChip correlation to peak-trough blood concentration in apixaban and rivaroxaban subjects (N=24 enrollment closed).

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Sells Xprecia Stride and a broad hemostasis analyzer portfolio (BCS, CA-series). Comparable as an established POC and central-lab coagulation diagnostics incumbent that ClotChip would compete against for hospital and clinic placements.

TypeBroad incumbent
Description

Operates CoaguChek, the dominant point-of-care INR/coagulation monitoring system, and a global leader in central-lab hemostasis diagnostics. Directly comparable because it serves the same anticoagulation monitoring use case that ClotChip targets, with broad global distribution and recurring reagent revenue.

TypeEmerging player
Description

Development-stage company focused on novel hemostasis and trauma diagnostics, with prior U.S. Department of Defense backing. Comparable as an emerging POC coagulation player with a defense/trauma angle similar to XaTek's DOD partnership.

TypeEmerging player
Description

Developer of Sonoclot, a viscoelastic POC coagulation analyzer for surgical and trauma settings. Comparable as a smaller, focused POC coagulation diagnostics company serving overlapping perioperative and trauma markets with a different underlying technology.

TypeDirect peer
Description

Developer of Quantra, a point-of-care viscoelastic hemostasis analyzer for perioperative and trauma settings. Most direct comparable: a venture-backed POC coagulation diagnostics company targeting similar perioperative/trauma use cases with a different underlying technology.

6Abbott
TypeBroad incumbent
Description

i-STAT system is a widely deployed POC platform with a coagulation cartridge. Comparable because it occupies the same bedside, finger-stick/coag cartridge workflow that ClotChip targets, and benefits from Abbott's hospital sales infrastructure.

TypeBroad incumbent
Description

Specialized hemostasis diagnostics company with STA analyzers and reagents for central labs. Comparable as a focused coagulation diagnostics competitor that defines the standard-of-care hemostasis assay that ClotChip is positioned as more accessible than.

8Haemonetics
TypeBroad incumbent
Description

Blood and plasma component management company with TEG thromboelastography platform for perioperative and trauma coagulation assessment. Comparable as a trauma/perioperative hemostasis diagnostics competitor and potential strategic acquirer for XaTek's trauma franchise.

TypeBroad incumbent
Description

Hemochron and ROTEM product lines cover POC and central-lab coagulation. Highly comparable as a specialized coagulation diagnostics incumbent with deep hospital relationships across both routine anticoagulation and trauma/perioperative testing.

TypeRegional player
Description

U.S.-based manufacturer of POC and specialty coagulation/hemostasis instruments. Comparable as a mid-sized specialty coagulation diagnostics competitor with overlapping POC product positioning, though typically serving U.S. clinical labs more than point-of-care ambulatory use.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

XaTek

Point-of-Care Blood Coagulation Diagnosticsclotchip.com

XaTek Inc. is a Cleveland, Ohio-based biomedical company developing ClotChip, a portable point-of-care device that uses miniaturized dielectric spectroscopy to assess whole-blood coagulation from a finger-stick sample. It targets hemophilia, DOAC monitoring, trauma, and pre-surgical clinical markets, and is currently in clinical trials following its 2020 FDA Breakthrough Device Designation.

What XaTek does

XaTek Inc. is a privately held, Cleveland, Ohio-based biomedical company founded in 2016 that develops ClotChip, a portable point-of-care medical device for assessing whole-blood coagulation. The device applies miniaturized dielectric spectroscopy — originally developed over eight years by an electrical engineering team at Case Western Reserve University — to single-drop whole-blood samples obtained via routine finger stick. ClotChip quantitatively measures blood impedance without requiring application-specific reagents and is agnostic to the underlying cause of a coagulation defect, enabling use across multiple clinical markets including congenital hemophilia, direct oral anticoagulant (DOAC) therapy monitoring, trauma-induced coagulopathy, and pre-surgical screening. The company received FDA Breakthrough Device Designation in March 2020 and remains in the clinical trials phase, with completed and ongoing studies across University Hospitals Cleveland (including Rainbow Babies & Children Hospital), the Cleveland VA, and Cleveland Clinic's Global Cardiovascular Innovations Center, as well as a DoD/U.S. Navy-funded ruggedization program for field trauma use.

XaTek operates a B2B enterprise sales motion targeting clinical care facilities, research centers, pharmaceutical companies, and device/diagnostic companies. The company is headquartered administratively in Hudson, Ohio, while maintaining laboratory operations at the Cleveland Clinic Global Cardiovascular Innovations Center. Leadership consists of President & CEO John Zak and a team described as experienced medical device market disrupters and inventors. The underlying revenue model is expected to be hardware sales of the ClotChip device to clinical institutions, with potential recurring revenue from consumables or service agreements, though the company is pre-commercial and no pricing, ARR, or revenue figures have been publicly disclosed. XaTek has raised at least $9.1 million in a disclosed funding round (July 2018) and operates with 1–10 employees, consistent with a clinical-stage medical device company preparing for regulatory clearance and commercial launch.

XaTek firmographics

Firmographics
Name
XaTek
Legal name
XaTek Inc.
Website
https://clotchip.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
XaTek Inc. is a Cleveland, Ohio-based biomedical company developing ClotChip, a portable point-of-care device that uses miniaturized dielectric spectroscopy to assess whole-blood coagulation from a finger-stick sample. It targets hemophilia, DOAC monitoring, trauma, and pre-surgical clinical markets, and is currently in clinical trials following its 2020 FDA Breakthrough Device Designation.
Ownership category
akta.pro rank

XaTek industry classification

Industry
Product category
Point-of-Care Blood Coagulation Diagnostics
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHACAD
Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLAHAFAI
Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms

Keywords

  • Point-of-care diagnostics
  • Blood coagulation testing
  • Hemostasis monitoring
  • Portable medical devices
  • Dielectric spectroscopy

Where XaTek is headquartered

Location

Headquarters

HQ city
Cleveland
HQ country
United States
HQ region
North America

Offices2 records

Markets served

XaTek business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales: ClotChip is a portable point-of-care medical device. Revenue model likely involves device sales to clinical facilities and healthcare providers, with potential recurring revenue from consumables or service agreements.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

XaTek product offering

Product offering

Core offering

XaTek Inc. develops and is commercializing ClotChip, a portable point-of-care medical device that uses proprietary miniaturized dielectric spectroscopy to evaluate whole-blood coagulation from a single finger-stick blood drop. The device delivers both quantitative and qualitative measurements of the hemostatic process without requiring application-specific reagents, and is intended for use in clinical care, trauma field assessment, anticoagulant therapy monitoring, hemophilia management, and pre-surgical screening. The company is pre-commercial with the device currently in clinical studies after receiving FDA Breakthrough Device Designation in March 2020.

Product overview

XaTek offers a single unified product: ClotChip, a portable point-of-care device for blood coagulation assessment. ClotChip leverages proprietary miniaturized dielectric spectroscopy technology to analyze whole-blood samples and provide rapid clinical evaluation of coagulation at the point of care, serving markets including congenital blood disorders, anticoagulant therapy monitoring, trauma care, and pre-surgical screening.

Differentiator

Problem solved

Functional benefit

Brands

  • ClotChip: A portable, point-of-care device capable of providing both quantitative and qualitative measurements relevant to a patient's entire hemostatic process using miniaturized dielectric spectroscopy.

Products and services

  • ClotChip ClotChip is a portable, point-of-care medical device that uses proprietary miniaturized dielectric spectroscopy to analyze single-drop whole-blood samples obtained from a routine finger stick. The device provides both quantitative and qualitative measurements relevant to a patient's entire hemostatic process, detecting both non-cellular (coagulation factors) and cellular (platelet) abnormalities without requiring application-specific reagents. It serves clinical care facilities, hemophilia treatment centers, anticoagulant therapy monitoring, trauma care, and pre-surgical screening use cases.

Quantifiable outcome

  • Currently in clinical trials - N=100 pre-surgical screening study completed
  • +3 more outcomes

Companies that use XaTek

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

XaTek technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

XaTek partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core.

  • U.S. Food and Drug Administration (FDA)coreOthers · 1 March 2020FDA granted Breakthrough Device Designation to ClotChip in March 2020, providing expedited review pathway and regulatory recognition of the device's potential to provide more effective treatment or diagnosis of life-threatening diseases.
  • U.S. Navy / Department of DefensecoreStrategic or Co-development Partner · 1 January 2019Department of Defense's Combat Readiness Medical Research Program, in cooperation with the U.S. Navy, funded the ruggedization of ClotChip for field use in trauma settings including ambulances and helicopters.
  • Case Western Reserve UniversitycoreTechnology or IntegrationTechnology origin - Case Western Reserve University electrical engineering team developed dielectric spectroscopy technology over more than eight years. XaTek licensed/commercialized this technology.
  • Cleveland Clinic - Global Cardiovascular Innovations CentercoreStrategic or Co-development PartnerCollaborative research partnership for device development and testing. XaTek maintains laboratory facilities at this location.
  • University Hospitals of ClevelandcoreStrategic or Co-development PartnerMultiple clinical trials including hypercoagulability in COVID-19 infections study and hemophilia sensitivity studies (N=100). Active research partnership for clinical validation.
  • U.S. Department of Veterans Affairs, ClevelandcoreStrategic or Co-development PartnerClinical study on ClotChip correlation to peak-trough blood concentration in apixaban and rivaroxaban subjects (N=24 enrollment closed).

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

XaTek competitors and assessment

Company assessment

Broad incumbents

  • Siemens Healthineers: Sells Xprecia Stride and a broad hemostasis analyzer portfolio (BCS, CA-series). Comparable as an established POC and central-lab coagulation diagnostics incumbent that ClotChip would compete against for hospital and clinic placements.
  • Roche Diagnostics: Operates CoaguChek, the dominant point-of-care INR/coagulation monitoring system, and a global leader in central-lab hemostasis diagnostics. Directly comparable because it serves the same anticoagulation monitoring use case that ClotChip targets, with broad global distribution and recurring reagent revenue.
  • Abbott: i-STAT system is a widely deployed POC platform with a coagulation cartridge. Comparable because it occupies the same bedside, finger-stick/coag cartridge workflow that ClotChip targets, and benefits from Abbott's hospital sales infrastructure.
  • Diagnostica Stago: Specialized hemostasis diagnostics company with STA analyzers and reagents for central labs. Comparable as a focused coagulation diagnostics competitor that defines the standard-of-care hemostasis assay that ClotChip is positioned as more accessible than.
  • Haemonetics: Blood and plasma component management company with TEG thromboelastography platform for perioperative and trauma coagulation assessment. Comparable as a trauma/perioperative hemostasis diagnostics competitor and potential strategic acquirer for XaTek's trauma franchise.
  • Werfen (Instrumentation Laboratory): Hemochron and ROTEM product lines cover POC and central-lab coagulation. Highly comparable as a specialized coagulation diagnostics incumbent with deep hospital relationships across both routine anticoagulation and trauma/perioperative testing.

Emerging players

  • Entegrion: Development-stage company focused on novel hemostasis and trauma diagnostics, with prior U.S. Department of Defense backing. Comparable as an emerging POC coagulation player with a defense/trauma angle similar to XaTek's DOD partnership.
  • Sienco: Developer of Sonoclot, a viscoelastic POC coagulation analyzer for surgical and trauma settings. Comparable as a smaller, focused POC coagulation diagnostics company serving overlapping perioperative and trauma markets with a different underlying technology.

Direct peers

  • HemoSonics: Developer of Quantra, a point-of-care viscoelastic hemostasis analyzer for perioperative and trauma settings. Most direct comparable: a venture-backed POC coagulation diagnostics company targeting similar perioperative/trauma use cases with a different underlying technology.

Regional players

  • Helena Laboratories: U.S.-based manufacturer of POC and specialty coagulation/hemostasis instruments. Comparable as a mid-sized specialty coagulation diagnostics competitor with overlapping POC product positioning, though typically serving U.S. clinical labs more than point-of-care ambulatory use.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

XaTek social profiles

Digital presence

XaTek compliance and trust

Trust signal

Compliance1 record

XaTek financial estimates

Financial estimate

Revenue estimate

Valuation estimate

XaTek leadership team

Management profile

Number of profiles

Profiles1 record

XaTek funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

XaTek M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about XaTek

What does XaTek do?

XaTek Inc. develops and is commercializing ClotChip, a portable point-of-care medical device that uses proprietary miniaturized dielectric spectroscopy to evaluate whole-blood coagulation from a single finger-stick blood drop. The device delivers both quantitative and qualitative measurements of the hemostatic process without requiring application-specific reagents, and is intended for use in clinical care, trauma field assessment, anticoagulant therapy monitoring, hemophilia management, and pre-surgical screening. The company is pre-commercial with the device currently in clinical studies after receiving FDA Breakthrough Device Designation in March 2020.

Is XaTek a public or private company?

XaTek is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was XaTek founded?

XaTek was founded in 2016. It employs 1 to 10 people.

Where is XaTek based?

XaTek is headquartered in Cleveland, United States, in the North America region.

How does XaTek make money?

One revenue line is on record: medical Device Sales.

Who are XaTek's main competitors?

Broad incumbents on record are Siemens Healthineers, Roche Diagnostics, Abbott, Diagnostica Stago, Haemonetics and Werfen (Instrumentation Laboratory). Emerging players are Entegrion and Sienco. HemoSonics is listed as a direct peer. Helena Laboratories is listed as a regional player.

Does XaTek have an API?

No public API is recorded for XaTek.

What industry is XaTek in?

XaTek's product category is Point-of-Care Blood Coagulation Diagnostics. Its primary akta.pro industry code is HLAHACAD, Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry), with a secondary code of HLAHAFAI, Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals